Corcept Therapeutics INC: directors' dealings · United States · SEC (Form 4)

About Corcept Therapeutics INC

Corcept Therapeutics Inc. (ticker: CORT) is a U.S.-listed biopharmaceutical company trading on the NASDAQ market in the United States. Headquartered in Redwood City, California, Corcept is best viewed as a specialized endocrinology and oncology company rather than a broad diversified pharma group. Founded in 1998, the company built its reputation around cortisol modulation, a scientific platform focused on blocking the effects of cortisol in serious diseases. Its first major commercial milestone was Korlym® (mifepristone), which received FDA approval in 2012 for the treatment of hypercortisolism, commonly known as Cushing’s syndrome. That product established Corcept’s core commercial base and remains central to its identity, but the company has since broadened its ambitions materially. Corcept’s competitive position is anchored in a narrow but differentiated therapeutic niche: glucocorticoid receptor antagonism. In biopharma, that kind of platform can matter because it creates a more defensible scientific franchise than a single-asset strategy, provided the company continues to generate convincing clinical data. Corcept is currently pursuing several programs across endocrinology, oncology, metabolism, and neurology. Its lead pipeline candidate is relacorilant, which is being developed in Cushing’s syndrome and in certain cancers, including platinum-resistant ovarian cancer. The company is also advancing additional cortisol-modulating compounds in indications such as metabolic liver disease and ALS, reflecting a strategy to extend its core biology into multiple high-unmet-need markets. From a business perspective, Corcept’s revenue profile has historically been driven primarily by Korlym sales in the United States, with commercialization and regulatory expansion becoming increasingly important. Recent developments are especially relevant for investors. In 2026, Corcept announced FDA approval of Lifyorli™ (relacorilant) in combination with nab-paclitaxel for women with platinum-resistant ovarian cancer, a meaningful step toward diversifying the company’s revenue base beyond its legacy Cushing’s franchise. At the same time, relacorilant continued to be reviewed by the FDA for Cushing’s syndrome, with a PDUFA date of July 11, 2026 for that filing, making near-term regulatory execution a major catalyst. The company has also been involved in patent litigation with Teva over Korlym, underscoring the importance of intellectual-property protection for its commercial products. Geographically, Corcept remains predominantly U.S.-focused, though it is increasingly seeking broader regulatory and commercial opportunities as its pipeline matures. Overall, CORT combines a marketed rare-disease franchise with a deeper late-stage pipeline, but the investment case remains highly dependent on regulatory outcomes, clinical-readout quality, and patent protection — all typical risk factors for a NASDAQ-listed specialty biopharma company in the United States.